Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AC Immune S.A. (NQ: ACIU )

4.130 -0.070 (-1.67%)
Streaming Delayed Price Updated: 3:36 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AC Immune S.A.

< Previous 1 2 3 4 Next >
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
Via Benzinga
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
From AC Immune SA
Via GlobeNewswire
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Via Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024
ACIU stock results show that AC Immune missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Gold Down Over 1%; AC Immune Shares Spike Higher
Via Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression. 
Via Benzinga
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
TransCode Therapeutics stock is down on Monday after the company announced plans for a shareholder meeting for RNAZ investors. 
Via InvestorPlace
Why Is Safe & Green Development (SGD) Stock Down 5% Today?
Safe & Green Development stock is down on Monday as SGD investors learn of a Form D filing with the SEC for a securities sale. 
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Is AC Immune (ACIU) Stock Up 45% Today?
AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
ACIU stock results show that AC Immune beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
From AC Immune SA
Via GlobeNewswire
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
From AC Immune SA
Via GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
From AC Immune SA
Via GlobeNewswire
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with... 
Via Benzinga
AC Immune Announces Pricing of Underwritten Offering of Common Shares
From AC Immune SA
Via GlobeNewswire
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
From AC Immune SA
Via GlobeNewswire
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
From AC Immune SA
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.